Showing results (41-50 of 80) with videos related to
Sort By:
Pageof 8
Neoplasia (New York, N.Y.)|February 4, 2010
Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survivalAdam Clauss, Vivian Ng, Joyce Liu, et al.International Journal of Clinical Oncology|April 21, 2010
Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancerSusana M Campos, Suzanne T Berlin, Leroy M Parker, et al.Nature Communications|August 30, 2017
Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug responseIoannis K Zervantonakis, Claudia Iavarone, Hsing-Yu Chen, et al.Gynecologic Oncology|April 3, 2019
Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancerJennifer Taylor Veneris, Elizabeth K Lee, Emily A Goebel, et al.International Journal of Clinical Oncology|November 7, 2022
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumorsSusana Campos, Ursula Matulonis, Suzanne Berlin, et al.The New England Journal of Medicine|March 29, 2012
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancerJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.Oncology Letters|September 14, 2019
Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild-type disease during the early disease courseJung-Min Lee, Dana-Adriana Botesteanu, Yusuke Tomita, et al.Annals of Surgical Oncology|March 8, 2021
Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian CancerBeryl L Manning-Geist, Mackenzie W Sullivan, Vishnudas Sarda, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancerSharmila Makhija, Lukas C Amler, Dana Glenn, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 10, 2024
Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trialRobert L Coleman, Domenica Lorusso, Ana Oaknin, et al.Pageof 8